These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
680 related articles for article (PubMed ID: 20686178)
1. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178 [TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Polivka J; Janku F Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502 [TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635 [TBL] [Abstract][Full Text] [Related]
4. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206 [TBL] [Abstract][Full Text] [Related]
5. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Hales EC; Taub JW; Matherly LH Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475 [TBL] [Abstract][Full Text] [Related]
6. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683 [TBL] [Abstract][Full Text] [Related]
7. Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells. Yang KJ; Piao L; Shin S; Shin SY; Li Y; Lee H; Tran Q; Park J; Hong S; Brazil DP; Hemmings BA; Kim SH; Park J Anticancer Res; 2017 Oct; 37(10):5415-5423. PubMed ID: 28982851 [TBL] [Abstract][Full Text] [Related]
8. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. Huang B; Porter G Acta Pharmacol Sin; 2005 Oct; 26(10):1253-8. PubMed ID: 16174443 [TBL] [Abstract][Full Text] [Related]
9. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Sun Z; Wang Z; Liu X; Wang D Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988 [TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Costa RLB; Han HS; Gradishar WJ Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298 [TBL] [Abstract][Full Text] [Related]
11. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231 [TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Hernandez-Aya LF; Gonzalez-Angulo AM Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469 [TBL] [Abstract][Full Text] [Related]
13. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452 [TBL] [Abstract][Full Text] [Related]
14. Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation. Riera MF; Regueira M; Galardo MN; Pellizzari EH; Meroni SB; Cigorraga SB Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E914-23. PubMed ID: 22275758 [TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
18. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101 [TBL] [Abstract][Full Text] [Related]
19. Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors. Isoyama S; Yoshimi H; Dan S; Okamura M; Seki M; Irimura T; Yamori T Biol Pharm Bull; 2012; 35(9):1607-13. PubMed ID: 22975517 [TBL] [Abstract][Full Text] [Related]
20. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Han S; Khuri FR; Roman J Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]